
|Videos|September 9, 2021
Should NPDR patients be treated with anti-VEGF agents?
Author(s)OTE Staff Reports
Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Dr Jennifer Sun, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
3
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











